Case Report: Successful treatment of severe pneumocystis carinii pneumonia in a case series of primary nephrotic syndrome after receiving anti-CD20 monoclonal antibody therapy

Rituximab is emerging as a new steroid sparing agent in children with difficult-to-treat nephrotic syndrome due to its ability of depleting CD20-positive B cells. Life-threatening adverse events such as pneumocystis carinii pneumonia may occur even though it seems to be well tolerated. Since rituxim...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Lili, Zheng, Weihua, Wang, Ping, Wu, Ying, Zhu, Guanghua, Yang, Rong, Gu, Li, Huang, Wenyan, Kang, Yulin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pediatrics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9845562/
https://www.ncbi.nlm.nih.gov/pubmed/36683820
http://dx.doi.org/10.3389/fped.2022.1067634

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9845562/
https://www.ncbi.nlm.nih.gov/pubmed/36683820
http://dx.doi.org/10.3389/fped.2022.1067634

Ejemplares similares